Eli Lilly Acquires Kelonia Therapeutics in Record $7 Billion Deal to Advance In Vivo Cancer Gene Therapies

Eli Lilly has announced the acquisition of Kelonia Therapeutics, a biotech startup specializing in innovative cancer treatments.

The deal is valued at up to $7 billion, including $3.25 billion upfront and potential milestone payments of $3.75 billion.

Kelonia's Revolutionary Technology

Kelonia develops in vivo gene therapies that reprogram patients' T-cells directly inside the body to target cancer cells.

This approach promises a simpler, off-the-shelf alternative to existing CAR T-cell therapies, potentially improving accessibility and speed.

Funding History and Partnerships

Kelonia emerged from stealth four years ago with a $50 million Series A led by investors like Alta Partners, Horizons Ventures, and Venrock.

Two years later, it formed a research partnership with Xyphos Biosciences, a subsidiary of Astellas Pharma, to advance immuno-oncology therapeutics.

Strategic Impact on Biotech Landscape

This acquisition marks the largest purchase of a venture-backed private biotech in over a decade, highlighting surging interest in in vivo therapeutics.

Lilly's move follows its recent buy of Orna Therapeutics for up to $2.4 billion, signaling a broader industry trend.

Comparable deals include AbbVie's $2.1 billion acquisition of Capstan Therapeutics and Bristol Myers Squibb's $1.5 billion purchase of Orbital Therapeutics.

Future Prospects for Cancer Treatment

Kelonia's pipeline features promising early clinical results for a multiple myeloma treatment, poised for acceleration under Lilly's resources.

The partnership could transform cancer care by enabling rapid, scalable gene therapies with better patient outcomes.

Industry experts view this as a pivotal step toward mainstream adoption of next-generation genetic medicines.